What is Oruka Therapeutics, Inc.'s cumulative cost basis?

Oruka Therapeutics, Inc. (ORKA) reported cumulative cost basis of $492.33M in Q1 2026.

How has Oruka Therapeutics, Inc.'s cumulative cost basis changed year-over-year?

Oruka Therapeutics, Inc.'s cumulative cost basis increased by 33.5% year-over-year, from $368.84M to $492.33M.

Oruka Therapeutics, Inc. ORKA Cumulative Cost Basis

Cumulative Cost Basis at other companies

Johnson & JohnsonJNJ

——

AmgenAMGN

——

AbbVieABBV

——

Arcutis Biotherapeutics, Inc.ARQT

——

ImmunityBio, Inc.IBRX

——

Spyre Therapeutics, Inc.SYRE

——

Other financials

Income statement

See full

Revenue-—

Operating income-$36.4M-45.2%

Net income-$31.8M-51.5%

EPS (diluted)-$0.46+93.4%

Balance sheet

See full

Cash & equivalents$49.5M-40.7%

Total debt$1.8M+90.8%

Total equity$486.7M+33.4%

Total assets$504.5M+33.8%

Cash flow

See full

Operating cash flow-$23.6M-13.0%

CapEx$73.0K+462%

Free cash flow-$23.7M-13.3%

Valuation

See full

Market cap$5.03B+533%

Returns & leverage

See full

Return on equity-27.3%-11.1pp

Debt / equity0×0.0×

Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Oruka Therapeutics, Inc.'s cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Oruka Therapeutics, Inc.'s cumulative cost basis?: Oruka Therapeutics, Inc. (ORKA) reported cumulative cost basis of $492.33M in Q1 2026.
How has Oruka Therapeutics, Inc.'s cumulative cost basis changed year-over-year?: Oruka Therapeutics, Inc.'s cumulative cost basis increased by 33.5% year-over-year, from $368.84M to $492.33M.